Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Table 2

Depression treatment pattern among adults with MS and depression (NAMCS-NHAMCS 2005–2011).

	Unweighted freq	Wt. freq (millions)	Wt.%
Overall depression treatment	133	1.205	57.25
Overall psychotherapy use	18	0.094	4.48
Overall antidepressant use	126	1.169	55.54
Antidepressant class and individual antidepressant use
SNRI	32	0.417	35.04
Desvenlafaxine	2	0.117	10.04
Duloxetine	13	0.208	17.76
Venlafaxine	18	0.092	7.85
SSRI	78	0.651	55.67
Citalopram	9	0.062	5.32
Escitalopram	19	0.154	13.16
Fluoxetine	20	0.234	20.05
Paroxetine	5	0.096	8.18
Sertraline	25	0.105	8.99
TCAs	11	0.07	3.32
Amitriptyline	4	0.015	1.25
Desipramine	1	0.003	0.29
Doxepin	2	0.043	3.63
Nortriptyline	4	0.009	0.80
Serotonin Modulators	12	0.107	5.08
Trazodone	12	0.107	5.08
Miscellaneous	15	0.147	6.97
Bupropion	11	0.069	3.25
Mirtazapine	4	0.078	3.72

Note. Based on 220 (nationally representative weighted million) ambulatory visits of adults (age ≥ 18 years) with Multiple Sclerosis and depression using NAMCS and NHAMCS 2005–2011 data.
MS: Multiple Sclerosis; Wt.: weighted; freq: frequency; NAMCS: National Ambulatory Medical Care Survey; NHAMCS: National Hospital Ambulatory Medical Care Survey.
Did not observe use of the following antidepressants: Amoxapine, Clomipramine, Imipramine, Maprotiline, Protriptyline, Trimipramine, Vilazodone, Vortioxetine, and Nefazodone.